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Background. Scleroderma is an autoimmune disease with a characteristic vascular pathology. The vasculopathy associated
with scleroderma is one of the major contributors to the clinical manifestations of the disease. Methodology/Principal
Findings. We used immunohistochemical and mRNA in situ hybridization techniques to characterize this vasculopathy and
showed with morphometry that scleroderma has true capillary rarefaction. We compared skin biopsies from 23 scleroderma
patients and 24 normal controls and 7 scleroderma patients who had undergone high dose immunosuppressive therapy
followed by autologous hematopoietic cell transplant. Along with the loss of capillaries there was a dramatic change in
endothelial phenotype in the residual vessels. The molecules defining this phenotype are: vascular endothelial cadherin, a
supposedly universal endothelial marker required for tube formation (lost in the scleroderma tissue), antiangiogenic interferon
a (overexpressed in the scleroderma dermis) and RGS5, a signaling molecule whose expression coincides with the end of
branching morphogenesis during development and tumor angiogenesis (also overexpressed in scleroderma skin. Following
high dose immunosuppressive therapy, patients experienced clinical improvement and 5 of the 7 patients with scleroderma
had increased capillary counts. It was also observed in the same 5 patients, that the interferon a and vascular endothelial
cadherin had returned to normal as other clinical signs in the skin regressed, and in all 7 patients, RGS5 had returned to
normal. Conclusion/Significance. These data provide the first objective evidence for loss of vessels in scleroderma and show
that this phenomenon is reversible. Coordinate changes in expression of three molecules already implicated in angiogenesis or
anti-angiogenesis suggest that control of expression of these three molecules may be the underlying mechanism for at least
the vascular component of this disease. Since rarefaction has been little studied, these data may have implications for other
diseases characterized by loss of capillaries including hypertension, congestive heart failure and scar formation.
Citation: Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, et al (2008) Capillary Regeneration in Scleroderma: Stem Cell Therapy
Reverses Phenotype?. PLoS ONE 3(1): e1452. doi:10.1371/journal.pone.0001452
INTRODUCTION
Progressive systemic sclerosis, or scleroderma, is an uncommon
connective tissue disease characterized by autoimmunity, diffuse
fibrosis[1] in the skin and internal organs, and a vasculopathy with
intimal hyperplasia of muscular and elastic arteries[2,3]. Ray-
naud’s phenomenon, an excessive vasospastic reaction to cold or
stress[4], precedes diagnosis of scleroderma by months or years[5],
and is early evidence of the vasculopathy associated with
scleroderma. The vasculopathy in scleroderma can result in non-
healing ulcers, gangrene and digit loss[6], clinical features rarely
encountered in primary Raynaud’s disease.
Further evidence of endothelial damage in scleroderma are
findings by nail fold capillaroscopy [7]. Typical findings include
giant capillaries, hemorrhages, avascular areas and neovascular-
ization[8]. This morphology resembles malformed capillary beds
formed in response to vascular endothelial growth factor [9] and
could be the result of increased levels of vascular endothelial
growth factor produced in response to ischemia resulting from
vasospasm and intimal hyperplasia[10]. Increased levels of
vascular endothelial growth factor (VEGF) are known to be
present in scleroderma[11] and high levels of VEGF are normally
associated with increased angiogenesis. Instead there appears to be
a loss of capillaries. Unfortunately, the prevailing belief that there
is loss of capillaries in scleroderma is based on findings in nail fold
capillaroscopy and is dependent on seeing columns of blood. The
ischemia caused by Raynaud’s phenomenon, especially coupled
with malformations caused by high levels of VEGF could cause
capillary collapse and could be misinterpreted as loss of capillaries
since nail fold microscopy would be unable to identify unperfused
capillaries. Definitive evidence for rarefaction, as opposed to loss of
capillary blood flow or malformation of newly formed vessels,
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[8,9], requires histological studies using endothelial specific
markers[12].
Capillary rarefaction has been identified, to our knowledge, in
only three other pathologic entities: congestive heart failure,
granulation tissue and hypertension[13,14]. Some researchers
have suggested that rarefaction may contribute to the character-
istic elevation in peripheral re´sistance in hypertension[14].
Scleroderma patients can also have cardiac failure associated with
pulmonary fibrosis and pulmonary hypertension[15,16] but a link
has not been found between the rarefaction in scleroderma and
that in cardiac failure, and scleroderma patients are, as a group,
hypotensive[17] rather than hypertensive.
To investigate the vasculopathy associated with scleroderma we
examined protein and mRNA molecules in endothelial cells and
capillaries of skin biopsies from patients with diffuse cutaneous
scleroderma and normal controls. In addition, we retrospectively
studied skin biopsies from diffuse cutaneous scleroderma patients
enrolled in a pilot study of the effect of high-dose immunosup-
pressive therapy and autologous hematopoietic cell transplantation
(HDIT/HCT)[18]. After HDIT/HCT, these patients all experi-
enced significant clinical improvement[19] including decrease in
the dermal fibrosis[19,20] and the modified Rodnan skin score
(MRSS) and an increase in overall function as measured by the
modified Health Assessment Questionnaire Disability Index
(MHAQ) . We analyzed biopsies from these patients, both before
and after treatment, and have demonstrated a correlation between
changes in tissue expression of angiogenesis related molecules and
capillary numbers.
RESULTS
Scleroderma vessels lost normal endothelial
markers and gained inflammatory markers
Normal dermal endothelium is characterized by several charac-
teristic immunohistochemical markers including: CD31, a com-
mon blood group antigen (Ulex europaeus lectin), von Willebrand
factor, and VE cadherin[21]. The most widely used of these is
CD31, which also stains leukocytes[22]. We found the expected
vascular labeling of vessels in normal and scleroderma skin, with
some positive leukocytes. Endothelium in capillary loops and
precapillary arterioles in normal skin are also positive for
enzymatic activity of endogenous alkaline phosphatase[23].
Figure 1 (A and B) depicts normal and scleroderma biopsies
where serial sections have been stained with CD31 and Ulex
europaeus lectin. In scleroderma skin a population of vessels have no
luminal staining for Ulex europaeus lectin whereas normal skin has
robust staining in all vessels. Von Willebrand factor, VE cadherin
(Figure 1 C), and alkaline phosphatase all showed similar marked
loss of luminal stain.
Immunohistochemical and histochemical stain quantification
showed significant loss in vessels in scleroderma biopsies for Ulex
europaeus lectin (p = 0.01), alkaline phosphatase (p = 0.002), VE
cadherin (p = 0.008), and von Willebrand factor (p = 0.033)
(Table 1 Section A). The difference in sample numbers tested
for each marker is a function of scarcity of tissue and when the
IHC was done. Some samples were very small and IHC was done
for only a few markers. Endothelial markers were scored according
to presence of positive and negative vessels. Numbers of biopsies
with vessels that all had stain on the endothelial cells are expressed
as number of positive biopsies per total n. All endothelial markers
showed a decrease in expression in scleroderma except CD31.
We assessed the vasculature for signs of endothelial inflamma-
tion and summarized the quantitative results in Table 1 B. High
endothelial venules have been described in dermal vessels of
chronic dermopathies and are considered a sign of chronic
inflammation[24]. The high endothelial venule phenotype has
endothelial nuclei projecting into the lumen with characteristic
proteins on the endothelial surface that provide a specialized site
for lymphocyte migration [25]. CD123, CD62P, and smooth
muscle actin are among the proteins expressed on inflamed
vascular lumens[26,27]. Scleroderma patients clearly had in-
creased inflammatory markers of endothelial cells compared to
normal controls. The endothelial cells in scleroderma were found
to have significantly increased expression of CD123 (high
endothelial venule, p = 0.0005) and smooth muscle actin
(p = 0.000001) although CD62P did not show a significant
difference (p = 0.49). CD123+ (high endothelial venules), and
smooth muscle actin staining patterns are depicted in Figure 1 D
and E respectively.
Figure 1. Endothelial Phenotype of Capillaries in Scleroderma
Compared to Normal Controls. Markers of normal endothelium: A.)
CD31 staining highlights capillaries in both scleroderma and normal
controls. B.) Black arrows show Ulex europaeus lectin (Ulex) is lost from
some vessels in scleroderma (compare with CD31 above). C.) VE
Cadherin stain is lost from some vessels in scleroderma (arrows)
whereas all vessels in normal skin are positive for VE cadherin. Both von
Willebrand factor and alkaline phosphatase were similarly lost from
scleroderma were similarly lost from scleroderma (data not shown)
Markers of inflamed endothelium: D.) CD123, a marker for high
endothelial venules, is increased in scleroderma as is E.) smooth muscle
actin (SMA). In the capillaries (arrows) smooth muscle actin stain
extends to the very top of the dermal papilla, unlike normal skin where
smooth muscle actin stain ends at the superficial horizontal plexus
(doubleheaded arrow). SMA staining is also increased in the media of
vessels in the reticular dermis, (data not shown)
doi:10.1371/journal.pone.0001452.g001
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Other markers of inflammation not limited to endothelial cells
were significantly increased in scleroderma compared to normal
tissue (quantitative results summarized in Table 1C). Immunohis-
tochemical stains for VCAM1 and ICAM1 were elevated and
statistically significant (p,0.05), consistent with published data for
higher expression in scleroderma compared to normal[28], and
cells positive for p selectin glycoprotein ligand 1(p = 0.0001),
interleukin-1a (p = 0.0005) and protease activated receptor 2
(p = 0.007) were all increased in scleroderma compared to normal
controls (quantitative results summarized in table 1 C). PAR2
appeared concentrated in smooth muscle and endothelial cells,
with some positive cells scattered in the dermis biopsies
(photomicrographs not shown). PAR2 is expressed in response to
inflammatory stimuli and in turn appears to enhance endothelial
proliferation, angiogenesis and immune mediator production
resulting in a neurologically mediated itch [29–31], a clinical
phenomenon seen often in early diffuse cutaneous scleroderma
[30,32–34]. IL-1a and PSGL1 were similarly increased both in
endothelial cells and in cells present in the dermal microvascular
unit (photomicrographs not shown). IL-1a activates complex
pathways in endothelial cells, dramatically affecting function.
PSGL1 is the high affinity counter receptor for selectins and is
constitutively expressed on some kinds of inflamed endothelium
[35]and PSGL1-selectin interactions play a role in homing and
entry of inflammatory cells into sites of inflammation[36].
Scleroderma skin had an infiltrate of CD123+cells,
an increase in interferon a mRNA expression and
downstream signaling markers of interferon
While looking at high endothelial venules in scleroderma skin
(above), we found a population of strongly CD123+ cells infiltrating
the dermis. Scleroderma dermis had many CD123+cells in the
superficial horizontal plexus, significantly more than normal skin
(p = 0.000005, Table 1D). CD123+ cells known as plasmacytoid
dendritic cells are the primary producers of interferon a in the
human body[37]. To look for the presence of interferon a mRNA
expression we used IFNA1 and IFNA2 RNA in situ probes to look for
expression of interferon a mRNA. 100% of Scleroderma patients
were positive for interferon a and 0% of the normal had interferon a
(p = 0.0001). Normal skin showed no detectable hybridization in the
dermis and occasional faint hybridization in the epidermis whereas
scleroderma tissue always expressed interferon a mRNA in the
dermis and epidermis. The interferon a+cells, probably plasmacy-
toid dendritic cells, were present next to small vessels in the
superficial horizontal plexus in the upper dermis (Figure 2 B). In situ
results were repeated 3 times and results were consistent.
To further confirm the presence of interferon a, we used
staining for downstream markers of type 1 interferon activity.
Canonical type 1 interferon signaling involves the binding of type
1 interferon (interferon a b or v) to the type 1 interferon receptor,
activation of the JAK/STAT pathway, and phosphorylation of
STAT1[38]. Presence of phosphorylated STAT1 in the nucleus of
cells STAT1 dimerization with another phosphorylated STAT
and translocation into the nucleus. STAT1 phosphorylation was
present in cellular nuclei in 7 of 10 scleroderma biopsies (depicted
in Figure 2 C), but negative in all 7 normal controls tested
(p = 0.006, Table 1 D).
Scleroderma skin had increased mRNA expression of
RGS5 and no sign of endothelial death or
proliferation
The apparent loss of capillaries in scleroderma led us to look for
increased expression of RGS5 mRNA. We found that both RGS5
mRNA expression was significantly increased in scleroderma
(Table 1 D). RGS5 is a regulator of G protein coupled receptor
signaling with cardiovascular properties[39] and specific associa-
tion with arteries[40]. For as yet unknown reasons, RGS5 is
expressed in pericytes that coat angiogenic vessels and appearance
of this gene correlates with loss of the ability to branch[41]. RGS5
in situ probes showed ,1RGS5+cells in normal skin. The same
probes hybridized with .10 cells per hpf cells in the 7 of 8 biopsies
of scleroderma skin, both in a perivascular distribution, and
scattered throughout the dermal matrix in cells that seem to be
myofibroblasts. There was a strong signal in the epidermis of the
scleroderma patient as well (Figure 2 D).
For the same reasons we looked at RGS5 we looked for direct
evidence of endothelial cell death and/or signs that vessels were
growing to replace the lost capillaries. To assess for signs of
apoptosis, the tissue was examined for nuclear changes character-
istic of apoptosis and stained for the apoptotic marker cleaved
caspase 3 [42] (Table 1 E). Cleaved Caspase 3 staining is recorded
Table 1. Molecular markers of microvascular phenotype,
inflammation and cell cycle in skin biopsies from scleroderma
compared to controls.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Type of molecular marker
Normal
#pos/n{
Scleroderma
#pos/n{ P value {
A) Endothelial markers
Alkaline Phosphatase 4/4 0/8 0.002
VE Cadherin 4/6 0/10 0.008
CD31 13/13 13/13 1
Von Willebrand Factor 3/3 1/7 0.033
Ulex Europaeus Lectin 10/14 3/14 0.01
B. Inflammatory endothelial markers
CD123 (high endothelial venules) 1/12 12/16 0.0005
VCAM1 0/4 5/5 0.007
ICAM1 0/3 5/5 0.017
CD62P 0/7 1/7 0.49
Smooth muscle actin 0/15 12/12 0.000001
C. Other inflammatory markers
PAR2 0/4 5/5 0.007
PSGL1 0/7 8/8 0.0001
IL-1 a 0/6 7/7 0.0005
D. Other markers
RGS5 in situ 0/5 7/8 0.004
Interferon a in situ (IFNA1 and IFNA2) 0/6 9/9 0.0001
CD123 (plasmacytoid dendrtic cells) 1/12 14/16 0.000005
STAT1 0/7 7/10 0.006
E. Endothelial cell death (apoptosis)
Cleaved Caspase 3 0/7 0/17 1
F. Perivascular cell Turnover:
Ki67 Antigen 0/8 11/11 0.00001
G. Endothelial cell turnover
Ki67 antigen 0/7 0/17 1
{Data are numbers biopsies with positive immunohistochemical, lectin and in
situ staining of skin biopsies over total number of biopsies available for
staining.
{P values were calculated with Fisher’s exact test using 262 frequency tables.
doi:10.1371/journal.pone.0001452.t001..
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as positive biopsies per total n. Numbers of caspase 3+cells per
high power field in the scleroderma biopsies fell within the normal
range. The only positive biopsy was one of the normal controls
(photomicrograph not shown) and the quantitative results were not
significantly different (p = 1). P values were calculated with Fisher’s
exact test using 262 frequency tables.
To assess endothelial replication, positive Ki67 antigen staining
was used to indicate the presence of cells in the biopsy that were in
the cell cycle, providing an estimate of proliferation. Ki67 staining
is expressed as number of positive biopsies per total n. Cells in the
follicles and epidermal layer were not counted. All biopsies were
scanned for cells lining the lumen that labeled positive with Ki67
and none were found. We scored the presence of Ki67+cells in
normal and scleroderma biopsies and carefully assessed cellular
morphology to establish whether or not endothelial cells were
proliferating (Table 1 F and G.). Comparison of Ki67 stain
between scleroderma and normal skin biopsies demonstrated no
endothelial cells in cell cycle in the superficial horizontal plexus or
anywhere else in any of the biopsies of normal or scleroderma skin
(Figure 2 E). Ki67+cells were found only in a perivascular
distribution. With no evidence that endothelial cells are prolifer-
ating in the scleroderma biopsies, we suggest that there is no
ongoing endothelial cell replacement.
Scleroderma had a decreased numbers of capillaries
Finally, to confirm that rarefaction exists in scleroderma, we
quantified the number of vessels present in normal and
scleroderma skin biopsies. Vessel counts based on finding red
blood cells can be misleading when vessels are collapsed; therefore
we used the presence of CD31 to define vascular profiles. We
compared average numbers of vessels per high power field
between forearm skin sections from 21 scleroderma patients and
13 site-matched normal controls. To determine if blood vessels
decrease during the course of disease, we counted biopsies from
our patient group whose disease duration was 2 years or less, and
compared vessel density to biopsies whose disease duration was
five years or greater and compared both disease groups to normal
vessel counts (Figure 3A). The numbers of vessels per high power
field in scleroderma was virtually identical both early (2 years or
less) and late in disease (5 or more years) and there was no
statistically significant difference (p = 0.48). Vessel counts of
normal controls differed significantly compared with both early
(p = 0.02) and late (p = 0.04) scleroderma and showed that the
number of total vessels was decreased overall in scleroderma
(Figure 3 A). To approximate capillary numbers, profiles of vessels
were counted in skin sections stained with an antibody for CD31.
Profiles were defined as clusters of positive CD31 stained cells
within the dermis with no central lumen visible (Figure 3B). To
approximate the numbers of larger vessels and the remainder of
capillaries we counted lumens in the same sections. Lumens were
defined as clusters of CD31 stained cells with a central lumen
clearly visible (Figure 3B). Comparison of lumens and profiles
between controls and scleroderma (Figure 3C) show that profiles
were significantly decreased in scleroderma (p = 0.009) whereas
lumens were not. (p = 0.18). This suggests that vascular loss in early
diffuse scleroderma is in smaller vessels, likely representing
capillaries.
Scleroderma endothelia regained a normal
endothelial marker and lost inflammatory markers
after HDIT/HCT treatment
Next we evaluated biopsies from patients with scleroderma
who underwent HDIT/HCT. Our study of capillary counts,
IHC and in situ study included biopsies from 7 patients at
baseline and at a median of 5 (range 4–6) years after treatment. As
noted in table 2, the patients from the clinical trial whose skin
biopsies were evaluated for the effects of HDIT/HCT on the
microvasculature, all experienced improvement in clinical assess-
ment of scleroderma (results of clinical trial have been previously
published)[19], including activities of daily life, stamina, energy,
and shortness of breath. Each of the 7 patients also reported
improvement in range of motion, hand flexion and reduction in
skin tightening, and pathologically the degree of the dermal
fibrosis improved [19].
We looked at endothelial phenotype, comparing endothelial
marker expression by IHC, and found that alkaline phosphatase,
Ulex europaeus lectin, and von Willebrand factor did not return to
normal after HDIT/HCT. CD31 was consistently positive both
before and after HDIT/HCT. VE cadherin stain was absent in a
population of vessels in all baseline biopsies. No VE cadherin-
negative vessels were present in 5 of 7 biopsies after HDIT/HCT
(p = 0.01, Table 3A, see photomicrographs figure 4A and B for
CD31 and VE cadherin).
Figure 2. Non-Angiogenic Phenotype in Scleroderma Compared to
Normal Controls. A) There was increased staining in CD123 in
perivascular cells in the superficial horizontal plexus in skin biopsies
from scleroderma patients compared with normal controls. B)
Interferon a (IFNa) in situ hybridization exhibited a robust signal in
scleroderma but was absent from controls. C.) Nuclear staining of
phosphorylated STAT1 in scleroderma provided evidence of active
interferon signaling, with STAT1 phosphorylation, dimerization and
translocation to nucleus in response to interferon a. D.) RGS5, a marker
of pericytes and arterial smooth muscle had increased mRNA
expression in scleroderma in a perivascular distribution. E.) Ki67 a
marker of cell cycle, showed no sign of Ki67 labeling of the endothelial
cells in either normal controls or scleroderma. There was an increase in
Ki67 positive perivascular cells in scleroderma.
doi:10.1371/journal.pone.0001452.g002
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CD123+(high endothelial venules) endothelial cells significantly
decreased (p = 0.01) after HDIT/HCT in scleroderma patients,
although smooth muscle actin expression was not (p = 0.08).
Interferon a mRNA expression in scleroderma
decreased after HDIT/HCT treatment
Interferon a mRNA in situ hybridization, CD123 (plasmacytoid
dendritic cells) and STAT1 were all significantly decreased after
HDIT/HCT (Table 3C). At baseline, all 7 patients had markedly
high transcript levels of interferon a RNA both in the dermis and
epidermis whereas five of 7 patients after HDIT/HCT showed
loss of RNA hybridization for interferon a in the dermis and
epidermis (p = 0.01, see photomicrographs Figure 4C). The
marker for plasmacytoid dendritic cells, CD123, present in all
baseline biopsies preceding HDIT/HCT, was lost in 6 of 7
patients after HDIT/HCT (p = 0.01) To further confirm the loss
of interferon a expression, presence of nuclear phosphorylated
STAT1 was decreased (p = 0.001) after HDIT/HCT (Table 3B).
The decrease in signs of interferon a, CD123+plasmacytoid
dendritic cells and STAT1 may indicate that the interferon a
producing cells are destroyed or deactivated by treatment, and in
the context of the capillary counts below have interesting vascular
implications.
After HDIT/HCT scleroderma skin had decreased
mRNA expression of RGS5 and no sign of
endothelial death or proliferation
RNA in situ hybridization for RGS5 at baseline shows that 6 of 7
scleroderma patients had increased positive cells (p = 0.0023,
Table 3C). After HDIT/HCT, all 7 biopsies had less than one per
high power field (depicted in Figure 4D).
Biopsies before and after had numbers of perivascular cells in
cell cycle greater than normal (p = 0.09, Table 3D). Ki67 was not
seen in endothelial cells before and after HDIT/HCT (p = 1,
Table 3E). IHC for cleavage of caspase 3 and histological analysis
of the endothelial cells before and after HDIT/HCT showed very
little cell death (p = 1, Table 3F).
After HDIT/HCT, capillary numbers increased in
those patients who lost all interferon a expression,
and regained VE cadherin
To demonstrate whether capillary counts increase after treatment,
we quantified biopsies from the scleroderma patients who grew
back capillaries at baseline and after HDIT/HCT. Patients after
HDIT/HCT show significantly increasing capillary numbers
(p = 0.015, Figure 5). Most interesting, because of the mechanistic
implications, is the correlation of the capillary numbers with VE
cadherin and interferon a expression. All 7 patients showed
changes in interferon a and VE cadherin in baseline biopsies. In
the 5 patients where capillary counts increased, IHC for VE
cadherin was positive in all vessels (Table 4). In the same patients
where VE cadherin expression returned to normal, IFNA1 and
IFNA2 in situ hybridization (interferon a) was undetectable (Table 4,
see Figure 4 C for photomicrographs).
Late stage scleroderma did not resemble
scleroderma after treatment
Skin changes in scleroderma at a late stage of disease can include
some softening and reduction of symptoms[43,44]. These late
stage skin changes could be a potentially confounding factor for
the scleroderma patients after HDIT/HCT since their disease
duration spans 5 to 7 years after diagnosis. We therefore included
as a final control, 4 skin biopsies from patients with a similar
duration of disease (5–6 years from diagnosis). These biopsies were
compared to the biopsies of the 7 patients after HDIT/HCT.
Figure 3. Total Vessels Were Decreased and Capillaries in Scleroderma
Skin Were Selectively Decreased. A.) This data represents the total
number of vessels per hpf in 15 normal and 21 scleroderma skin biopsies
stained with CD31. The average vessels/hpf is significantly decreased in
scleroderma compared with normal controls (p=0.02). B.) Normal skin
IHC for CD31 demonstrates microvasculature. ‘‘Profiles’’ or capillaries are
defined as linear CD31 staining with no central lumen (single arrows) and
represent a robust estimate of capillary density. ‘Lumens’ represent larger
vessels, and are defined as structures positive for CD31 that have a central
lumen (circle). C.) Data are average numbers of ‘‘lumens’’ versus ‘‘profiles’’.
Average ‘‘lumens’’, representing larger vessels, in scleroderma skin
biopsies are not significantly different from normal skin (p=0.18).
Average ‘‘profiles’’, representing capillaries, are significantly decreased in
scleroderma compared with controls P =0.009. These results indicate that
capillaries are decreased in scleroderma.
doi:10.1371/journal.pone.0001452.g003
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We compared the IHC results after HDIT/HCT with four
patients whose disease duration is 5 years or longer. VE cadherin
was negative in scleroderma of long duration, 4 of 4 Non-HDIT/
HCT scleroderma patients of 5 years or greater scleroderma
duration still have vessels that do not express VE cadherin. 4 or
more years after HDIT/HCT however, 5 of 7 patients have
regained all VE cadherin expression in biopsies (p = 0.007, Table 5
A). VE cadherin expression has therefore returned only after
HDIT and is not an artifact of late stage disease.
The CD123+endothelial cells (high endothelial venules) has
resolved itself in 6 of 7 biopsies after HDIT/HCT, whereas Non-
HDIT/HCT patients with similar (5 years or greater) disease
duration all have CD123+ vessels with high endothelial morphol-
ogy (p = 0.017, Table 5B). Similarly the expression of interferon a
mRNA by in situ hybridization is undetectable in 5 of 7 biopsies,
whereas 2of four late stage disease patients have interferon a+ cells
in dermis (p = 0.047, Table 5C). The perivascular cells positive for
CD123 are also increased in late stage patients but have
disappeared in all but one of the post HDIT/HCT biopsies
(p = 0.017, Table 5C). Loss of the expression of interferon a,
absence of CD123+cells, as well as inflammation, appear also not
to be an artifact of late stage disease but seem to be associated with
HDIT/HCT. Limited amounts of available tissue prohibited us
from obtaining results for RGS5.
Profile counts showed a significant increase (p = 0.025) in the
average number of capillaries per hpf in the five patients who grew
back capillaries after HDIT/HCT, compared with Non-HDIT/
HCT scleroderma of 5–6 years duration (Figure 5).
DISCUSSION
In this study, the most impressive changes in the dermis of
scleroderma patients were rarefaction of capillary loops, loss of
expression of VE cadherin, and the appearance of mRNA for
interferon a and RGS5. While we also observed changes in other
molecules, the changes in these three molecules are particularly
relevant because they have all been reported to play possible
critical roles in angiogenesis. We also report that after HDIT/
HCT the above changes reverse, especially when increasing
capillary counts are found in the tissue. We showed that these
changes are unlikely to be the result of the natural history of
scleroderma, and suggest that these findings may provide clues to
the pathogenesis of this poorly understood disease.
An endothelial phenotype that lacks normal markers is a puzzle
and to the best of our knowledge this is previously unreported.
One extreme possibility is that endothelial cells no longer line the
vessels. We do not think this is true. On two samples of normal and
Table 2. Clinical and pathological findings after HDIT and HCT correlated with vessel counts.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patient #
Specimen
Code #
Time after
HDIT/HCT (years)
Before HDIT/HCT
vessels count
After HDIT/HCT
Vessels count
Drop in MRSS
after HDIT/HCT
Drop in dermal fibrosis
After HDIT/HCT
Change in MHAQ score
After HDIT/HCT
9 0942 6 6.8 7.7 16 3 1 to 0
11{ 1105 5 6.14 7.9 30 5 2.5 to 0
12{,D 1226 1 8.2 8 1 0.75 to 0
18 1888 5 5.2 12 18 3 2.125 to 1.5
22J,£ 2218 4 6.59 3.43 22 4
24 2435 4 5.09 8.78 6 4 2.875 to 2.375
26£ 2622 4 5.7 4.4 34 4 2.875 to 0.125
For each of the clinical parameters assessed, post-HDIT/HCT values were compared to pre-HDIT/HCT (baseline) values at the last time point in each of several post-HDIT/
HCT time windows
{Reported finger contractures as the only indication of evidence of scleroderma post HDIT/HCT.
{No clinical or pathologic data is available for the first 4 years post HDIT/HCT. Patient subsequently underwent right lower lobectomy 4 years 9 months post HDIT for
squamous cell carcinoma.
Jdeveloped pulmonary hypertension.
£did not have increased capillary counts in post HDIT/HCT biopsies.
Ddid not have a count done on the one year biopsy and clinical data was not available for four year biopsy
Abbreviations: mRSS-Modified Rodnan Skin Score for dermal fibrosis; MHAQ–modified Health Assessment Questionnaire Disability Index
doi:10.1371/journal.pone.0001452.t002..
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Table 3. Molecular markers of microvascular phenotype,
inflammation and cell cycle in skin biopsies from scleroderma
before and after HDIT/HCT
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Type of molecular marker
Before
HDIT/HCT
# pos/n{
After
HDIT/HCT
# pos/n{ P value{
A) Endothelial markers
Alkaline Phosphatase 0/7 0/7 1
VE Cadherin 0/7 5/7 0.010
CD31 6/7 7/7 0.49
Von Willebrand Factor 1/7 4/7 0.13
Ulex Europaeus Lectin 2/7 3/7 0.49
B Inflammatory
CD123 (high endothelial venules) 6/7 1/7 0.01
Smooth muscle actin 5/5 2/5 0.08
C. Other :
RGS5 in situ 6/7 7/7 0.0023
Interferon a in situ (IFNA1 and IFNA2) 7/7 2/7 0.01
STAT1 6/6 0/6 0.001
CD123 (plasmacytoid dendritic cells) 6/7 1/7 0.01
D. Perivascular cell Turnover:
Ki67 Antigen 7/7 5/7 0.01
E Endothelial cell turnover
Ki67 antigen 0/7 0/7 1
Cleaved Caspase 3 0/7 0/7 1
{Data are numbers of biopsies with positive immunohistochemical, lectin and in
situ staining of skin biopsies over total number of biopsies available for
staining.
{P values were calculated with Fisher’s exact test using 262 frequency tables.
doi:10.1371/journal.pone.0001452.t003..
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scleroderma skin, we performed electron microscopy (data not
shown). The luminal cells of these samples lacked features of other
cell types, which can, under some circumstances, form a lining.
For example, we looked for the microplicated surface of
macrophage or the altered polarity and microfilaments charac-
teristic of smooth muscle cells and found none of these
characteristics in the luminal cells in scleroderma vessels. One
could speculate a variety of mechanisms to explain endothelial
cells without normal markers: 1) differentiation of a cell type other
than normal dermal microvascular endothelial cells into an
endothelial-like morphology, which replaced the dead endothelial
cells early in disease; 2) circulating precursors from other
endothelial lineages (e.g. sinus, lymphatic) replace the normal
dermal endothelial cell; 3) activating autoantibodies to endothelial
cells or other circulating factors, which cause them to differentiate
into an abnormal state and/or cause chronic inflammation; 4)
effect of a pathological cell type on the endothelial cell expressome,
or 5) an underlying mechanism or structural abnormality existent
in scleroderma endothelial cells responsible for some part of the
vascular abnormality similar to that found in the children of
patients with malignant hypertension[45].
The bulk of capillaries in the skin are capillary loops branching
from the superficial horizontal plexus into the rete pegs and consist
of a single layer of endothelium with a few pericytes all above the
border of the rete ridge[46]. This is a highly specific structure,
optimized to improve thermal exchange. Our data showed that
capillary loops, are lost from scleroderma skin at a very early stage.
This loss was associated with a dramatic and unusual loss of
expression of markers used to define the endothelial cell lineage
including VE cadherin. We found significant loss of the smallest
vessels in the baseline scleroderma skin biopsies (all 2 years or less
from diagnosis). The low number of vessels appeared to remain
constant at all stages of disease. After HDIT/HCT the endothelial
marker which did return to normal in 5 of 7 patients, VE
cadherin, is a calcium dependent cell adherens junction protein
responsible during development for aggregation of cells and
formation of endothelial tubes[47]. The loss of VE Cadherin in
baseline scleroderma and the reappearance of VE cadherin after
HDIT/HCT may be significant in terms of the angiogenic
potential of the skin, since the same 5 patients whose VE cadherin
expression returned to normal also increased the numbers of
capillaries present in their skin.
RGS5 mRNA expression was reversed in all 7 patients after
treatment, and did not correlate specifically with regeneration of
capillaries, since two of the seven did not increase average skin
capillary numbers. This indicate that decreased RGS5 expression
after HDIT/HCT is insufficient to regenerate capillaries by itself,
but like the VE Cadherin data may suggest that some form of
vasostatic process in scleroderma inhibited any angiogenic
response prior to treatment. The hypothesis exists that part of
pathogenesis of scleroderma is circulation of an endothelial toxic
agent, loss of circulating endothelial precursors or some other less
specified dysregulation of the angiogenic pathway[48,49]. How
Figure 4. Immunohistochemistry and in situ results before and after
HDIT/HCT show regain of VE cadherin and loss of RGS5 and
Interferon a. A.) Immunohistochemistry for CD31 before and after
HDIT and autologous HCT is positive in both biopsies, whereas B) when
compared with CD31 stained biopsies above, VE cadherin is negative
before but positive after HDIT and HCT. C.). Baseline biopsies of
scleroderma patients prior to HDIT and autologous HCT all showed cells
positive for interferon a (IFNa) in situ hybridization and were present
both in the vasculature and scattered in the matrix. After HDIT and
autologous HCT, interferon amRNA was undetectable in 5 of 7 biopsies.
Compared biopsies were run at the same time with the same conditions
and probe concentration. D) In situ hybridization for RGS5 demonstrates
positive mononuclear cells around vessels and some cells scattered in
the matrix in the scleroderma biopsies prior to treatment with HDIT/
HCT. There was little or no detectable RGS5 mRNA after HDIT/HCT.
doi:10.1371/journal.pone.0001452.g004
Figure 5. Capillary Counts Increase After HDIT and HCT Compared to
Baseline and to Scleroderma of Long Duration. Data are average
‘‘profiles’’/hpf counted in scleroderma patients before (Baseline) and after
(After HDIT/HCT) treatment with HDIT and HCT. ‘‘Late disease’’ are
average ‘‘profiles’’/hpf in a separate group of patients with disease
duration similar to patients after HDIT/HCT, included to provide an
additional disease control. Baseline (biopsies for patients who grew back
capillaries) had an average capillary number of 4.1/hpf. After HDIT/HCT,
average capillary number (for patients who increased capillary number)
rose to 5.8/hpf (p=0.015). Patients with a disease duration of 5 or more
years averaged 3.8 profiles/hpf and when compared with the patients
who grew back capillaries(After HDIT/HCT) yielded a p value of 0.025.
doi:10.1371/journal.pone.0001452.g005
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this relates to the loss of VE cadherin and the appearance of RGS5
is not at all obvious.
Interferon a is a cytokine known to be a potent inhibitor of
angiogenesis[50,51]. Type 1 interferon has been found to be present
in epithelial layers and epidermis in humans and identified as an
endogenous inhibitor of angiogenesis in skin[52]. Interferon a
treatment has been associated with new onset or exacerbation of
scleroderma and Raynaud’s phenomena with digital gangrene[53–
55]. A type 1 interferon gene expression signature has been
described in autoimmune connective tissues diseases, including
scleroderma[56–58]. We found CD123+ interferon-producing
cells[59] at the superficial horizontal plexus where the bulk of
capillaries would be, and where angiogenesis should be taking place.
Furthermore, increased STAT1 expression in the same areas
confirms the presence of an interferon response. The evidence that
expression of interferon a mRNA was decreased 5 of 7 patients
undergoing HDIT/HCT combined with the unexpected observa-
tion of vascular regeneration suggest that an antiangiogenic state
may have been reversed by this treatment. We are unaware of any
other study that has shown reversible rarefaction in any disease.
Intriguingly, the two patients interferon a expression was still present
were the same two patients that did not grow new capillaries and had
vessels negative for VE Cadherin.
Existing observations suggest that vascular disease is paramount
in the pathogenesis of scleroderma[60,61]. Certainly vasospasm, as
in Raynaud’s, is a frequent, though not a clearly obligatory
precursor to disease. It is also possible that rarefaction precedes
diagnosis of scleroderma by many years and our data suggest this
may be the case. There are no objective data of which we know
showing elevated levels of cell death or apoptosis in any phase of
this disease. Suggestions that apoptosis and rarefaction occur
during active disease have been based on studies showing the
presence of circulating factors able to kill endothelial cells in
culture[62] but the relevance to endothelial death in vivo is not
known. Similarly, endothelial autoantibodies in scleroderma have
been classified as anti-microvascular and are cited by some as a
cause of vessel loss[63,64]. Once again, these data are limited to in
vitro studies that may not represent in vivo phenomena. Our studies
were of skin biopsies only and, especially in the context of the
HDIT/HCT trial, fresh tissue samples were limited. Given the
number of possible circulating factors which may cause the death
of endothelial cells or prevent their growth, it may be best in future
studies to approach this problem with a discovery biology
approach (such as proteomics or gene expression arrays) rather
than a direct method. Also, since the natural history of the disease
tends to decrease the levels of inflammatory factors as the disease
moves from an inflammatory to a chronic sclerotic phase, it may
not be possible to find significant differences without much larger
numbers of patients than we have in this study. A larger study is
underway and, given the clinical success of this one, and we may
be able to assess antiendothelial antibodies and other circulating
factors together with a more detailed assessment of cell death. We
found no evidence of ongoing endothelial cell death in the
scleroderma skin compared with normal controls, and must
conclude that any endothelial cell death in scleroderma, implied
by capillary rarefaction, must be an early or episodic event in
scleroderma. To further support the suggestion that capillaries are
lost very early, we found no evidence that capillary numbers
continue to drop over time in scleroderma.
If active capillary loss is occurring, there should be angiogenesis
and vessel replacement in the superficial horizontal plexus at the
post capillary venule[65] involving endothelial proliferation[66].
The pattern of malformed vessels seen in nail beds is, in fact,
reminiscent of patterns of angiogenesis seen with localized over
expression of VEGF[67,68]. Evidence published by others that
circulating and local VEGF is increased in scleroderma has led to
a dilemma. How can elevated VEGF be correlated with loss of the
microvasculature? In the scleroderma dermis we see no evidence
of endothelial replication in the superficial horizontal plexus
Table 4. Increased vessel number following HDIT/HCT is correlated with return of normal immunohistochemical expression of VE
cadherin and a interferon in skin biopsies in late stage scleroderma
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patient #
Change in Average
vessel/hpf
Time after HDIT/
HCT (years)
Before HDIT/HCT
VE cadherin
Before HDIT/HCT
interferon a
After HDIT/HCT
VE cadherin
After HDIT/HCT
interferon a
9 +0.9 6 neg pos pos neg
11 +1.8 5 neg pos pos neg
12 +2.6 4 neg pos pos neg
18 +7 5 neg pos pos neg
22{ 23.2 4 neg pos neg pos
24 +3.7 4 neg pos pos neg
26{ 21.3 4 neg pos neg pos
{these 2 patient’s skin biopsies had decreased numbers of vessels
doi:10.1371/journal.pone.0001452.t004..
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Table 5. Scleroderma Patients after HDIT/HCT with Capillary
Regeneration, Compared with Patients of Similar Disease
Duration
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Type of molecular marker
After HDIT/
HCT #
pos/n{
Same disease
duration #
pos/n{ P value{
A) Endothelial Markers
CD31 7/7 4/4 1
VE Cadherin 5/7 0/4 0.007
B Inflammatory markers
CD123 (high endothelial venules) 0/5 3/3 0.017
C. Other Markers
Interferon a in situ (IFNA1 and IFNA2) 0/5 2/2 0.047
CD123 (plasmacytoid dendritic cells) 0/5 3/3 0.017
{Data are numbers of biopsies with positive immunohistochemical, lectin and in
situ staining of skin biopsies over total number of biopsies available for
staining.
{P values were calculated with Fisher’s exact test using 262 frequency tables.
doi:10.1371/journal.pone.0001452.t005..
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suggesting that there is no angiogenic response but we have not
found a good explanation for this conundrum.
A possible mechanism for the return of capillaries, consistent
with the effects of HDIT/HCT is that endothelial precursor cells
are required for angiogenesis[69–71]. An infusion of the CD34-
selected hematopoietic cell graft may have therefore contributed to
the re-capillarization. Unfortunately at the time of the HDIT/
HCT study, samples were not taken to analyze levels of circulating
endothelial cells. In future studies it may be an excellent way to
confirm that endothelial cells have returned to normal in
scleroderma. Alternatively, and in our opinion more likely,
HDIT/HCT is immunosuppressive and may be ablating some
cell that inhibits endothelial regeneration or produces a factor or
factors that inhibit endothelial cell regeneration. HDIT/HCT
treatment has been investigated for other autoimmune diseases
besides scleroderma including systemic lupus erythematosus and
multiple sclerosis. It has been previously reported that there was
recovery of CD4+ T cell counts after HDIT/HCT at 2 years after
HDIT/HCT. However, sustained responses were observed in
63% of patients at a median of 4 years[72]. Immune recovery
after HDIT/HCT is associated with increasing thymic-derived
naı¨ve CD4+ T cells with a decrease in memory T cells, an increase
in regulatory T cells, and broader clonal diversity than was present
before HDIT/HCT[72–74] These late immune changes support
the conclusion that sustained responses may have resulted from the
immunomodulatory effects of HDIT/HCT in addition to the early
immunosuppression and depletion of autoreactive T cells. After
HDIT/HCT, we observed that those patients who grew back
capillaries were different from scleroderma of long duration. The
patients who received HDIT/HCT had more capillaries and also
lost interferon a expression, and regained all VE cadherin
expression, whereas the scleroderma in late stages did not. The
interferon expression and CD123+cells are interesting in this
context since one of the functions of the plasmacytoid dendritic
cell is the breaking of tolerance[37], and it may be associated with
some of the changes in T cell populations. The high levels of
interferon a support the hypothesis that plasmacytoid dendritic
cells may be part of the pathogenesis of scleroderma. Interferon a
is antiproliferative in vivo[75]. The high local levels of interferon a
in scleroderma skin may therefore be preventing the formation of
new capillaries directly.
In conclusion we propose that rarefaction is an early and
possibly ‘‘pre-diagnosis’’ event in scleroderma. This capillary loss is
associated with a change in endothelial phenotype of the
remaining vessels that has not been previously described. The
phenotype of these residual vascular structures appears to be
mildly inflammatory but not apoptotic, with no sign of endothelial
replication or replacement. We hypothesize that the presence of
interferon a, the loss of VE cadherin and the presence of RGS5 are
involved in the process which appears to keep the vessels static and
produce fibrosis in this poorly understood disease. We report
regeneration of capillaries and resolution of the non-angiogenic
phenotype after HDIT/HCT. Our studies were somewhat limited
by the retrospective nature, however, future planned studies of this
autologous protocol and an allogeneic protocol will include
capillaroscopic, ultrasound and MRI microvascular assessment
in a subset of patients in the hope of defining these microvascular
changes and assessing clinical importance. Regulation of VE
cadherin expression, function of RGS5 producing smooth muscle,
appearance of interferon a at other sites of vascular rarefaction,
and the apparent ablation by HDIT/HCT of some cell involved
in the inhibition of angiogenesis are obviously intriguing targets for
continued study. Rarefaction itself is not well studied in the known
examples of cardiac failure, hypertension and regression of
granulation tissue. Our studies may provide new clues to the
more general problem of capillary loss.
METHODS
Patients in the study
All tissues used in this study were biopsies supplied in collaboration
with Stanford University, the University of California San
Francisco, Boston University, Fred Hutchinson Cancer Research
Center, and the University of Washington, collected and analyzed
according to Institutional Review Board approved protocols for
human study at each respective institution. Normal controls
(Table 6) and scleroderma patient biopsies (Table 7) were supplied
as sets of formalin fixed paraffin embedded blocks or slides.
HDIT/HCT
The clinical trial of HDIT/HCT for patients with scleroderma has
been previously described[19]. Briefly, hematopoietic stem cells
were mobilized with granulocyte colony stimulating factor,
harvested from the peripheral blood by leukapheresis and then
CD34-selected. HDIT/HCT consisted of total body irradiation
(800 cGy) with partial lung shielding, high-dose cyclophosphamide
(120 mg/kg) and antithymocyte globulin (Pfizer Inc., New York,
NY). After HDIT/HCT, patients were transplanted with the
autologous CD34-selected hematopoietic cell graft.
Histochemistry
Tissue was stained with hematoxylin & eosin and Movat’s
pentachrome according to standard protocols. In addition to
these two stains, tissue was stained for endogenous alkaline
phosphatase. Briefly, the sections were cut, dewaxed with xylene
and rehydrated with ethanol series prior to pretreatment with
100 mM glycine and 0.3% Triton X-100. They were then allowed
to develop overnight in 5-Bromo-4-Chloro-39-Indolyphosphate p-
Toluidine Salt/Nitro-Blue Tetrazolium Chloride (Roche). Coun-
terstain is Nuclear Fast Red (Vector Labs). The slides were
mounted with Aquamount (VWR Scientific).
Immunohistochemistry (IHC)
Antibodies are listed in Table 8 with dilution, manufacturer and
clone number and secondary antibody.
In-lab IHC Briefly, our protocol for IHC is as follows:
paraffin sections were dewaxed and rehydrated prior to antigen
retrieval using microwave method in sodium citrate pH 6.0. Slides
were placed in citrate buffer and microwaved for 20 minutes on
low power, allowed to cool and placed in blocking buffer for
30 minutes, incubated with primary antibody overnight at 4uC,
then washed and incubated with biotinylated secondary antibody
(Vector Labs Universal horse anti-mouse/rabbit/goat #BA-1300
or Vector Labs Universal horse anti-mouse/rabbit #BA-1400) for
30 minutes. After secondary antibody, the slides were washed and
incubated for 30 minutes with avidin biotin complex reagent
Blocking serum, and avidin biotin complex reagent were supplied
in Vector Elite Universal Kit (Vector Labs #PK6100). The slides
were washed again prior to detection with DAB with Nickel
Chloride to create a grey-black color (Vector Labs # SK-4100),
the slides were then counterstained with methyl green, dehydrated
in ethanol series, cleared in xylene and mounted with Permount
(Fisher Scientific).
Phenopath IHC Immunohistochemistry done at Phenopath
Labs (www.phenopath.com for their established protocols) is
indicated in Table 8, along with protocols optimized for each
antibody.
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RNA in situ hybridization
The protocol for RNA in situ including construction and
amplification of probe was based on the protocol in the Roche
DIG application manual[76]. Proteinase K digestion was performed
at a concentration of 5 mg/mL for 20 minutes. Probe concentra-
tions were 1 ng/uL and hybridizations were performed at 42uC
overnight. Post hybridization washes followed this protocol: low
stringency 4615 minutes at 37uC, then high stringency 2630 min-
utes at 55uC. Detection with alkaline phosphatase was performed
with anti DIG Fab (Roche) at a dilution of 1:500 and the chromogen
used was Vector Red (Vector Labs).
RNA Probe generation
Probe for RGS5 were made from plasmids with a 1.7 kb fragment
of human RGS5 long previously characterized and published by
us[40]. A 1.7 kb segment of DNA contaiing IFNA1 and a 2.2 kb
segment for IFNA2 were amplified from from a human Sanger
DNA library clone (#RP11-354P17 GenBank accession #
AL353732). The plasmids were subcloned using the Stratgene
pPCRScriptamp kit. In vitro transcription was performed with
DIG RNA labeling kit (Roche) and RNA was isolated (Agilent low
RNA input fluorescent linear amplification kit protocol, 2006
version 4, page 19). Standard controls using sense RNA probes
were run at the same concentration as the antisense probe with
each experiment and showed no specific signal. Positive and
negative tissue controls were included in every experiment as well
to confirm signal. Standard blast searches were done for the DNA
segments amplified and no major non-specific cross reactivity was
found to other human DNA. Blast searches were done against the
other interferon genes. Minor similarity found between interferon
a genes and IFNW. No similarity was found between the interferon
a genes and IFNB or IFNG.
Scoring methodology
All high power fields are at a magnification of 206.
Endothelial markers Platelet endothelial cell adhesion
molecule 1 (CD31) yielded a predictable staining pattern for all
three groups of patients, and was used as a control for the other
endothelial markers including von Willebrand factor, vascular
Table 6. Age, sex and anatomic location of skin biopsies from
normal controls
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patient# Age Sex Biopsy Location
1 un un scalp
2 un un un
3 un un scalp
4 45 F forearm
5 un un un
6 un un scalp
7 un un scalp
8 un un breast
9 un un abdomen
10 un un breast
11 50 F forearm
12 46 F forearm
13 51 F forearm
14 41 M forearm
15 41 F forearm
16 64 F forearm
17 36 M forearm
18 40 F forearm
19 59 F arm
20 47 F posterior shoulder
21 73 F lateral neck
22 37 F arm
23 54 F posterior neck
24 un un thigh
Abbreviations: un-unavailable
doi:10.1371/journal.pone.0001452.t006..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Table 7. Age, sex, disease subtype and duration and anatomic
site of skin biopsies of scleroderma patients
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patient# Age Sex Disease Type Biopsy Location Disease Duration
1a 47 F Diffuse Forearm 1 year
1b 48 ‘‘ 2 years
1c 51 ‘‘ 5 years
2a 44 F Diffuse Forearm 1 year
2b 46 ‘‘ 3 years
2c ‘‘ Back ‘‘
2d 48 Forearm 5 years
3 47 M Diffuse Forearm 1 year
4a 44 F Diffuse Forearm 1 year
4b ‘‘ Upper Arm 1 year
5 un M Diffuse un un
6 51 F Diffuse Forearm 1 year
7 33 M Diffuse Forearm 1.5 years
8 35 M Diffuse Forearm 1&emsp14;year
9 44 M Diffuse Forearm 6 months
10 28 F Diffuse Forearm 2.5 years
11 71 F Diffuse Forearm 6 months
12 33 F Diffuse Forearm 1.5 years
13 56 F Diffuse Forearm 8 months
14 46 F Diffuse Forearm 8 months
15 32 F Diffuse Forearm 10 months
16 44 F Diffuse Forearm 7 months
17 47 F Diffuse Forearm 2.5 years
18 39 F Diffuse Forearm 6 years
19 55 F Diffuse Forearm 9 months
20 40 M Diffuse Forearm 1&emsp14;year
21 44 F Diffuse Forearm 6 months
22 45 F Diffuse Forearm 5 years
23 un un Diffuse Upper Arm un
24 43 F Diffuse Forearm 15 months
25 37 F Diffuse Upper arm 7 months
26 50 F Diffuse Forearm 1&emsp14;year
27 46 F Diffuse Upper arm 11 months
28 40 F Diffuse Forearm 2 years
29 55 F Diffuse Forearm 2 years
30 36 M Diffuse Thigh 15 months
Abbreviations un = unavailable at this time
doi:10.1371/journal.pone.0001452.t007..
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endothelial (VE) cadherin, alkaline phosphatase and Ulex europaeus
lectin. Serial biopsies were stained with all 5 markers and vessels
(identified as clusters of cells positive for CD31) were compared. If
vessels were found that had CD31 stain but lacked another marker
in a serial section, the biopsy was scored as negative for that
marker. The observed negative and positive were recorded in 262
frequency tables.
RGS5 Stain score Normal biopsies hybridized with RGS5
probes showed 0-1 perivascular cells per high power field. Slides
that had more than 2 positive cells per high power field were
considered positive. Positive slides always had increased
perivascular expression, and some also had many cells positive
in the dermal matrix. Negative and positive were recorded in 262
frequency tables.
Interleukin-3 receptor alpha subunit (CD123) (high
endothelial venule phenotype), smooth muscle actin and P
selectin (CD62P) stain score Biopsies were examined for
presence or absence of lumens of blood vessels with endothelial
cells labeling with CD123, smooth muscle actin and CD62P.
Biopsies were scanned until positive vessels were located or until
entire biopsy had been examined. Biopsies with positive vessels
were recorded as positive. Negative and positive were recorded in
262 frequency tables.
Interferon a score Biopsies were scored according to the
presence or absence of positive stain anywhere in biopsy. Biopsies
with any stain color were scored as positive. Negative and positive
were recorded in 262 frequency tables.
Vascular cell adhesion molecule 1 (VCAM1), Intercellular
adhesion molecule 1 (ICAM1), interleukin-1 alpha (IL-1a), p
selectin glycoprotein ligand 1 (PSGL1), protease activated
receptor 2 (PAR2), Ki67 antigen (Ki67), CD123 (plasmacytoid
dendritic cells), and cleaved caspase 3 stain scores Normal
skin biopsies were examined and cells per high power field were
quantified. The mean of cells per high power field was calculated and
we assumed a normal distribution. We added two standard
deviations above the positive range and used that number as a
cutoff. Biopsies with an average number of cells higher than the
cutoff were scored as positive. Biopsies with an average number of
cells lower than the cutoff were scored as negative. Negative and
positive were recorded in 262 frequency tables.
Signal transducer and activator of transcription 1
(STAT1) stain score Cells with a nuclear stain were
considered positive. The numbers of positive cells were counted
in 3 high power fields and averaged. The normal skin biopsy range
was determined and 2 standard deviations were added to the top
of the range for a positive cutoff. Only biopsies with an average
number of stained nuclei per high power field greater than the
cutoff were considered positive. Negative and positive were
recorded in 262 frequency tables.
Capillary counts
For quantification purposes, we have used site-matched skin
biopsies, since capillary loops change in number from site to site.
Biopsies of normal, scleroderma and disease controls were stained
with CD31. Photographs of entire biopsy to be counted were taken
at 206 with an Olympus microscope and Spot camera. Two
separate blinded investigators counted the same set of photographs
and data are averages of the two counts. ‘‘Profiles’’ are defined as
CD31 stained vessels without a central lumen ‘‘Lumens’’ are
defined as CD31 stained vessels with central lumens. ‘‘Vessels’’ are
defined as the sum of lumens and profiles.
Statistics
The stain scores for IHC and RNA in situ hybridization were
recorded as frequency data and were analyzed for significance using
Fishers Exact Significance test. Frequency data were obtained
according to above scoring systems and 262 tables were used to
record differences between groups. P values were calculated with one
tailed probability value. Capillary quantification is a continuous
variable and was therefore tested for significance using the students’ t
test for independent variables. Values of p,0.05 were considered
significant. Standard error was calculated with the standard
deviation divided by the sq root of the N.
Table 8. Antibodies used for immunohistochemical analysis of skin biopsies.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Antibody Manufacturer Clone Pretreatment Dilution Secondary/Kit
Signal trasducer and activator of transcription 1 (STAT1){ CellSigTech Tyr701, 58D6 Citrate/heat 1:200 Biomouse/rabbit Elite
P Selectin (CD62P){ Abcam AK-6 Citrate/heat 1:500 Biomouse/rabbit Elite
P Selectin glycoprotein ligand 1 (PSGL1) { Abcam 3E2.25.5 PL1 Citrate/heat 1:200 Biomouse/rabbit Elite
Interleukin-1alpha (IL-1a) { R&D Systems Lot #AAB01 Citrate/heat 5 ug/mL Biomouse/rabbit/goat Elite
Vascular endothelial (VE) Cadherin{ Novocastra BV6 Citrate/heat 1:100 Vector Biomouse Elite
Platelet endothelial cell adhesion molecule 1 (CD31){ Novocastra 1A10 EDTA 1:400 Mouse/Envision
Ulex europaeus lectin{ Vector N/A pronase 1:200 Elite SA (no secondary)
Interleukin 3 receptor subunit alpha (CD123) { DAKO 7G3 PXXIV 1:250 Mouse/Envision
smooth muscle actin{ DAKO 1A4 pronase 1:250 Mouse/Envision
Protease activated receptor 2 (PAR2){ Zymed sam11 none 1:500 Mouse/Envision
Intercellular adhesion molecule 1 (ICAM1){ Chemicon Wcam1 Citrate/heat 1:200 Mouse/Envision
Vascular cell adhesion molecule 1 (VCAM1){ R&D Systems BBA19 EDTA 1:1000 Vector BioGoat/Elite
Ki67 antigen (Ki67){ DAKO MIB-1 Citrate/heat 1:200 Mouse/Enviision
Cleaved caspase 3{ Cell Sig Tech #9661 EDTA 1:200 Vector BioGoat/Elite
Von Willebrand factor{ DAKO M0616 pronase 1:100 Mouse/Envision
Detection for all IHC performed using 3,39-diaminobenzadine (DAB).
{In Lab IHC
{Phenopath IHC
doi:10.1371/journal.pone.0001452.t008..
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